Search
Search Menu

Re-evaluation of failed drugs and targets using contemporary knowledge, methodology and tools

Co-authored by PAASP’s managing partner, Anton Bespalov, the correspondence article ‘Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets’ was published last week in Nature Reviews Drug Discovery. Here, the authors discuss the great importance of 1. Data robustness, …

Read more

Development of an information sharing platform – Pharma shares unpublished results

F1000 Research has published an article entitled “In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis” co-authored by PAASP’s managing partner Anton Bespalov, together with colleagues from AbbVie, Servier, Pfizer and Alkermes. Independently of each other, …

Read more

Y47 Partnership

PAASP services aim to identify areas that need improvement and to provide our clients with the necessary tools. We believe that this process becomes successful only when the need for change is understood and driven from the inside of the clients’ organization. To that end, and …

Read more

DGGF Membership

DGGF Membership PAASP became a member of the DGGF (Deutsche Gesellschaft für Gute Forschungspraxis; German Society for Good Research Practice). The DGGF is the largest association in Germany focusing on quality management in the chemical and pharmaceutical industry. It was founded in 1995 with the aim to promote exchange …

Read more

Scroll Up